Evaluate the Safety and Explore the Efficacy of DWP712 With Moderate to Severe Glabellar Lines

Phase 1CompletedNCT06212960

Daewoong Pharmaceutical Co. LTD.20 enrolled

Overview

To evaluate the safety of 12-week administration of DWP712 inj. in subjects with moderate to severe glabellar lines.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Glabellar Lines

Interventions

DWP712BIOLOGICAL

Clostridium botulinum Toxin

BOTOX®BIOLOGICAL

Clostridium botulinum Toxin

Eligibility

Sex: ALLMin age: 19 YearsMax age: 65 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Subjects with facial wrinkle scale (FWS) score of visual appearance of glabellar lines ≥2 (moderate) at maximum frown as assessed by the investigator at screening Exclusion Criteria: \-

Locations (1)

Chung-Ang University Hosptial

Seoul, South Korea

Outcomes

Primary Outcomes

Number of occurrences for grade 3 or higher adverse drug reactions (ADRs) according to CTCAE 5.0

Time frame: At 4, 8, 12 week after the injection

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.